• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics closes $150m public offering

June 29, 2018 By Sarah Faulkner

SenseonicsSenseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds.

The Germantown, Md.-based company plans to use its newly-acquired funds to support the commercialization of its implantable continuous glucose monitoring system, Eversense.

“We are pleased with the results of this transaction and the support that we have received from the investment community,” president & CEO Tim Goodnow said in prepared remarks. “The funds provided from this offering meaningfully strengthen our balance sheet and will be instrumental in supporting a broad launch of Eversense in the United States.”

Earlier this month, the FDA approved the Eversense CGM for use in people with diabetes ages 18 and older. The device is the first to feature an implantable glucose sensor that can be worn for up to 90 days.

The system includes a small sensor that is implanted just below the skin in an outpatient procedure. The sensor continuously measures glucose levels and sends that data to a user’s mobile phone every five minutes, warning users if their glucose levels drop or rise out of range.

In a 125-person study, researchers compared data collected by the Eversense CGM with data from a lab-based glucose analyzer. Senseonics found that the proportion of people that experienced a serious adverse event with the implanted device was less than 1%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Funding Roundup, Patient Monitoring, Wall Street Beat Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS